Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03889574 · ClinicalTrials.gov registry record
Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization
A clinical trial of Cardiac Disease, sponsored by Methodist Health System.
- Completed
- Registry status
- 84
- Enrollment target
- 1
- Study location
NCT03889574 is a study of Cardiac Disease that has completed, run by Methodist Health System. The registered enrollment target is 84 participants, below the 819-participant average among 24 other Cardiac Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03889574, a study of Cardiac Disease, has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Aim(s)/Objective(s) * To evaluate the safety and efficacy of triple antithrombotic therapy in patients taking DAPT of aspirin and a P2Y12 inhibitor in addition to either a NOAC or warfarin for the prevention of thromboembolic or acute coronary syndrome (ACS) events in patients with non-valvular atrial fibrillation (AF), history of coronary artery disease (CAD)/stent placement or recurrent ACS event. * To determine the Methodist Health System (MHS) prescribing practices and patterns in cardiac patients with a history of AF who are admitted for CAD or an ACS event requiring PCI. Hypothesis Primary Hypothesis Cardiac patients with a history of AF and an indication for long-term NOAC who are also prescribed DAPT following an ASC event or revascularization with stenting will demonstrate a significant difference in cardiovascular outcomes and major bleeding events when compared with warfarin-based triple therapy.
Conditions Studied
Study Locations (1)
Texas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2019-06-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03889574
The ClinicalTrials.gov registry entry for NCT03889574 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 24 other Cardiac Disease trials with a reported enrollment target (90% lower). The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03889574 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03889574 about?
NCT03889574 is a clinical study titled "Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization". Aim(s)/Objective(s) * To evaluate the safety and efficacy of triple antithrombotic therapy in patients taking DAPT of aspirin and a P2Y12 inhibitor in addition to either a NOAC or warfarin for the prevention of thromboembolic or acute coronary syndrome (ACS) events in patients with non-valvular atr...
What is the current status of trial NCT03889574?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2019-02-26. Estimated completion is 2019-06-27.
What conditions does trial NCT03889574 study?
This clinical trial studies the following conditions: Cardiac Disease.
Who is sponsoring clinical trial NCT03889574?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03889574 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiac Performance System Data Collection Study - Minnesota
RECRUITING
-
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
RECRUITING
-
Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass
RECRUITING · NA
-
Rectus Sheath Block in Cardiac Surgery
RECRUITING · NA
-
Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)
RECRUITING
-
Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.